Home  »  Business   »  Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) Could Reall...

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) Could Really Rise To $27.00 In 12 Months, According To Analysts.

In last trading session, Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) saw 0.48 million shares changing hands with its beta currently measuring 0.74. Company’s recent per share price level of $4.29 trading at $0.1 or 2.39% at ring of the bell on the day assigns it a market valuation of $181.38M. That closing price of YMAB’s stock is at a discount of -377.39% from its 52-week high price of $20.48 and is indicating a premium of 31.47% from its 52-week low price of $2.94. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.73 million shares which gives us an average trading volume of 599.98K if we extend that period to 3-months.

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) trade information

Upright in the green during last session for gaining 2.39%, in the last five days YMAB remained trading in the green while hitting it’s week-highest on Wednesday, 11/23/22 when the stock touched $4.29 price level, adding 3.16% to its value on the day. Y-mAbs Therapeutics Inc.’s shares saw a change of -73.53% in year-to-date performance and have moved 9.44% in past 5-day. Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) showed a performance of -71.72% in past 30-days. Number of shares sold short was 3.71 million shares which calculate 11.15 days to cover the short interests.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Wall Street analysts have assigned a consensus price target of $14.63 to the stock, which implies a rise of 70.68% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $27.00. It follows that stock’s current price would drop -529.37% in reaching the projected high whereas dropping to the targeted low would mean a gain of 6.76% for stock’s current value.

Y-mAbs Therapeutics Inc. (YMAB) estimates and forecasts

Statistics highlight that Y-mAbs Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -59.94% of value to its shares in past 6 months, showing an annual growth rate of -109.38% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -1.50% in the current quarter and calculating 81.20% increase in the next quarter. This year revenue growth is estimated to rise 73.80% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $13.88 million for the same. And 8 analysts are in estimates of company making revenue of $27.03 million in the next quarter that will end on Dec 2022. Company posted $8.96 million and $9.6 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 54.80% while estimating it to be 181.60% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19.60% during past 5 years.

YMAB Dividends

Y-mAbs Therapeutics Inc. is more likely to be releasing its next quarterly report between February 22 and February 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)’s Major holders

Insiders are in possession of 12.33% of company’s total shares while institution are holding 67.96 percent of that, with stock having share float percentage of 77.53%. Investors also watch the number of corporate investors in a company very closely, which is 67.96% institutions for Y-mAbs Therapeutics Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at YMAB for having 2.98 million shares of worth $45.03 million. And as of Jun 29, 2022, it was holding 6.81% of the company’s outstanding shares.

The second largest institutional holder is Polar Capital Holdings Plc, which was holding about 2.95 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 6.75% of outstanding shares, having a total worth of $44.67 million.

On the other hand, Fidelity Select Portfolios – Biotechnology and AB Cap Fd.-AB Small Cap Growth Port are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 1.97 million shares of worth $29.79 million or 4.50% of the total outstanding shares. The later fund manager was in possession of 1.24 million shares on Aug 30, 2022, making its stake of worth around $20.02 million in the company or a holder of 2.85% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]